{'fraction_non_alphanumeric': 0.024147727272727272, 'fraction_numerical': 0.002840909090909091, 'mean_word_length': 4.7317073170731705, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Mupirocin to prevent S. aureus infections.

Infections at surgical sites remain an important cause of illness and death and substantially increase health care costs.1 Prevention is thus important not only for the safety of patients, but also in terms of cost effectiveness. In this issue of the Journal, Perl and colleagues2 report the results of a randomized trial that sought to prevent surgical-site infections due to Staphylococcus aureus. S. aureus is the most frequent cause of surgical-site infections and is more virulent than other frequent causes, such as coagulase-negative staphylococci and enterococci. S. aureus therefore accounts for a large proportion of the morbidity and mortality . . .